Jupiter, Florida – August 31, 2017 – Charleston Laboratories, Inc., announced that it has reacquired all US rights to develop and commercialize its hydrocodone pipeline products from Daiichi Sankyo Co., Ltd. and its US subsidiary, Daiichi Sankyo, Inc. This ends a three-year collaboration between the companies; Charleston Laboratories is now centralizing its comprehensive acute pain portfolio and accelerating the process to bring CL-108 to market.
“We thank Daiichi Sankyo for their partnership, and now with a singular focus, we are excited to rapidly execute our corporate strategy,” said Paul Bosse, President and Chief Executive Officer of Charleston Laboratories. The company will resubmit the CL-108 new drug application (NDA) in the coming weeks, and if approved, CL-108 can help the millions of acute pain patients who require an opioid analgesic while preventing or reducing opioid-induced nausea and vomiting (OINV).
“By addressing OINV, we believe that patients will achieve proper pain relief, shortened recovery time, and fewer days on opioid medication. Through decreasing a patient’s use of opioids, we aim to reduce the risk of misuse and abuse. Charleston Laboratories is dedicated to ensuring safe and responsible prescribing and use of our opioid analgesic portfolio,” said Bosse.
Two of the most common side effects experienced by patients taking opioids for acute pain management are nausea1,2 and vomiting1. In fact, approximately 40% of patients prescribed opioids for pain experience OINV.3,4 That translates to approximately 75 million instances of OINV in the US each year.3-7
OINV can be extremely burdensome for patients and presents barriers to achieving effective management of pain and recovery.3 Both healthcare professionals and patients have indicated that OINV was the primary reason for treatment discontinuation. Patients also stated a willingness to give up some degree of pain relief to mitigate the debilitating side effect that is OINV.3
The challenges of OINV are not limited to poor patient outcomes.3 The economic impacts of OINV include higher healthcare costs,3 longer recovery periods, and the need for additional patient care. Patients suffering from OINV showed increased utilization of inpatient and outpatient services, resulting in an increase of healthcare costs per patient, according to an analysis of claims data.3
Charleston Laboratories, Inc. is a privately held, specialty pharmaceutical company focused on the research, development and commercialization of novel pain products and technologies designed to prevent or reduce nausea and vomiting.
Charleston Laboratories’ product pipeline seeks to address unmet needs in Opioid-Induced Nausea and Vomiting (OINV) and Migraine-Associated Nausea and Vomiting (MANV). Charleston Laboratories intends to introduce novel pain therapies that reduce the burdensome side effects related to opioid analgesics and other products.
For more information, please visit www.charlestonlabs.com.
Didi Discar, Principal
References: 1. Rogers E, Mehta S, Shengelia R, Reid MC. Four Strategies for Managing Opioid Induced Side Effects in Older Adults. Clin Geriatr. 2013;21(4):1-14. 2. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105-S120. 3. Nicholson BD. Economic and clinical burden of opioid-induced nausea and vomiting. Postgrad Med. 2017;129(1):111-117. 4. Wood GJ, Shega JW, Lynch B, Von Roenn JH. Management of intractable nausea and vomiting in patients at the end of life: “I was feeling nauseous all of the time…nothing was working.” JAMA. 2007;298(10):1196-1207. 5. Smith HS, Smith JM, Seidner P. Opioid-induced nausea and vomiting. Ann Palliat Med. 2012;1(2);121-129. 6. IMS Institute for Healthcare Informatics. Use of opioid recovery medications: Recent evidence on state level buprenorphine use and payment types. IMS Health Incorporated: Parsippany, NJ, September 2016. 7. Volkow ND, McLellan TA, Cotto JH, Karithanom M, Weiss SR. Characteristics of opioid prescriptions in 2009. JAMA. 2011;305(13):1299-1301.